Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
Hetero
India - Hyderabad
LEVOFLOXACIN (levofloxacin) by Hetero is 12. Approved for nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens and 46 more indications. First approved in 2013.
Drug data last refreshed 18h ago
12.1 Mechanism of Action Levofloxacin is a member of the fluoroquinolone class of antibacterial agents [see ] . 12.3 Pharmacokinetics The mean ± SD pharmacokinetic parameters of levofloxacin determined under single and steady-state conditions following oral tablet, oral solution, or intravenous…
Worked on LEVOFLOXACIN at Hetero? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Fluoroquinolone Antibacterial
A Study of Levofloxacin Ocular Implant in Patients Undergoing Routine Bilateral Cataract Surgery
Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB
Levofloxacin Ocular Implant for Ocular Surgery
The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%
The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo